Cargando…

Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program

Melanoma plasticity creates a plethora of opportunities for cancer cells to escape treatment. Thus, therapies must target all cancer cell subpopulations bearing the potential to contribute to disease. The role of the differentiation/pigmentation program in intrinsic and acquired drug resistance is l...

Descripción completa

Detalles Bibliográficos
Autores principales: Czyz, Malgorzata, Sztiller-Sikorska, Malgorzata, Gajos-Michniewicz, Anna, Osrodek, Marta, Hartman, Mariusz L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636509/
https://www.ncbi.nlm.nih.gov/pubmed/31354817
http://dx.doi.org/10.1155/2019/1697913
_version_ 1783436075387060224
author Czyz, Malgorzata
Sztiller-Sikorska, Malgorzata
Gajos-Michniewicz, Anna
Osrodek, Marta
Hartman, Mariusz L.
author_facet Czyz, Malgorzata
Sztiller-Sikorska, Malgorzata
Gajos-Michniewicz, Anna
Osrodek, Marta
Hartman, Mariusz L.
author_sort Czyz, Malgorzata
collection PubMed
description Melanoma plasticity creates a plethora of opportunities for cancer cells to escape treatment. Thus, therapies must target all cancer cell subpopulations bearing the potential to contribute to disease. The role of the differentiation/pigmentation program in intrinsic and acquired drug resistance is largely uncharacterized. MITF level and expression of MITF-dependent pigmentation-related genes, MLANA, PMEL, TYR, and DCT, in drug-naïve and vemurafenib- or trametinib-treated patient-derived melanoma cell lines and their drug-resistant counterparts were analysed and referred to genomic alterations. Variability in execution of pigmentation/differentiation program was detected in patient-derived melanoma cell lines. Acute treatment with vemurafenib or trametinib enhanced expression of pigmentation-related genes in MITF-M(high) melanoma cells, partially as the consequence of transcriptional reprograming. During development of resistance, changes in pigmentation program were not unidirectional, but also not universal as expression of different pigmentation-related genes was diversely affected. In selected resistant cell lines, differentiation/pigmentation was promoted and might be considered as one of drug-tolerant phenotypes. In other resistant lines, dedifferentiation was induced. Upon drug withdrawal (“drug holiday”), the dedifferentiation process in resistant cells either was enhanced but reversed by drug reexposure suggesting involvement of epigenetic mechanisms or was irreversible. The irreversible dedifferentiation might be connected with homozygous loss-of-function mutation in MC1R, as MC1R(R151C  +/+) variant was found exclusively in drug-naïve MITF-M(low) dedifferentiated cells and drug-resistant cells derived from MITF(high)/MC1R(WT) cells undergoing irreversible dedifferentiation. MC1R(R151C  +/+) variant might be further investigated as a parameter potentially impacting melanoma patient stratification and aiding in treatment decision.
format Online
Article
Text
id pubmed-6636509
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-66365092019-07-28 Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program Czyz, Malgorzata Sztiller-Sikorska, Malgorzata Gajos-Michniewicz, Anna Osrodek, Marta Hartman, Mariusz L. J Oncol Research Article Melanoma plasticity creates a plethora of opportunities for cancer cells to escape treatment. Thus, therapies must target all cancer cell subpopulations bearing the potential to contribute to disease. The role of the differentiation/pigmentation program in intrinsic and acquired drug resistance is largely uncharacterized. MITF level and expression of MITF-dependent pigmentation-related genes, MLANA, PMEL, TYR, and DCT, in drug-naïve and vemurafenib- or trametinib-treated patient-derived melanoma cell lines and their drug-resistant counterparts were analysed and referred to genomic alterations. Variability in execution of pigmentation/differentiation program was detected in patient-derived melanoma cell lines. Acute treatment with vemurafenib or trametinib enhanced expression of pigmentation-related genes in MITF-M(high) melanoma cells, partially as the consequence of transcriptional reprograming. During development of resistance, changes in pigmentation program were not unidirectional, but also not universal as expression of different pigmentation-related genes was diversely affected. In selected resistant cell lines, differentiation/pigmentation was promoted and might be considered as one of drug-tolerant phenotypes. In other resistant lines, dedifferentiation was induced. Upon drug withdrawal (“drug holiday”), the dedifferentiation process in resistant cells either was enhanced but reversed by drug reexposure suggesting involvement of epigenetic mechanisms or was irreversible. The irreversible dedifferentiation might be connected with homozygous loss-of-function mutation in MC1R, as MC1R(R151C  +/+) variant was found exclusively in drug-naïve MITF-M(low) dedifferentiated cells and drug-resistant cells derived from MITF(high)/MC1R(WT) cells undergoing irreversible dedifferentiation. MC1R(R151C  +/+) variant might be further investigated as a parameter potentially impacting melanoma patient stratification and aiding in treatment decision. Hindawi 2019-07-03 /pmc/articles/PMC6636509/ /pubmed/31354817 http://dx.doi.org/10.1155/2019/1697913 Text en Copyright © 2019 Malgorzata Czyz et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Czyz, Malgorzata
Sztiller-Sikorska, Malgorzata
Gajos-Michniewicz, Anna
Osrodek, Marta
Hartman, Mariusz L.
Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
title Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
title_full Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
title_fullStr Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
title_full_unstemmed Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
title_short Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
title_sort plasticity of drug-naïve and vemurafenib- or trametinib-resistant melanoma cells in execution of differentiation/pigmentation program
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636509/
https://www.ncbi.nlm.nih.gov/pubmed/31354817
http://dx.doi.org/10.1155/2019/1697913
work_keys_str_mv AT czyzmalgorzata plasticityofdrugnaiveandvemurafenibortrametinibresistantmelanomacellsinexecutionofdifferentiationpigmentationprogram
AT sztillersikorskamalgorzata plasticityofdrugnaiveandvemurafenibortrametinibresistantmelanomacellsinexecutionofdifferentiationpigmentationprogram
AT gajosmichniewiczanna plasticityofdrugnaiveandvemurafenibortrametinibresistantmelanomacellsinexecutionofdifferentiationpigmentationprogram
AT osrodekmarta plasticityofdrugnaiveandvemurafenibortrametinibresistantmelanomacellsinexecutionofdifferentiationpigmentationprogram
AT hartmanmariuszl plasticityofdrugnaiveandvemurafenibortrametinibresistantmelanomacellsinexecutionofdifferentiationpigmentationprogram